Literature DB >> 29057971

PTEN-L promotes type I interferon responses and antiviral immunity.

Yuanyuan Cao1, Hongyun Wang1, Liu Yang2, Zhen Zhang1, Chenlin Li2, Xu Yuan2, Lang Bu2, Lang Chen2, Yu Chen1, Chun-Mei Li3, Deyin Guo1,3.   

Abstract

Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a well-known tumor suppressor that acts as a dual-specificity phosphatase and is frequently mutated in human cancer. Our previous work has demonstrated that PTEN also plays a vital role in type I interferon responses and antiviral innate immunity. Recently, a translational variant of PTEN with a long N-terminal extension (PTEN-L) has been discovered that is secreted into the extracellular environment and enters recipient cells, where it exerts a phosphatase function antagonistic to PI3K/Akt signaling and tumorigenesis. In this study, we demonstrate that PTEN-L promotes type I interferon responses and antiviral innate immunity during viral infection in a phosphatase activity-dependent manner. Compared with canonical PTEN, PTEN-L also exerts its antiviral function when it is applied exogenously in protein form. This finding was confirmed in cell cultures and mouse infection models. Furthermore, PTEN-L enhances the responses of both type I interferon and proinflammatory cytokines, thus suggesting that PTEN-L might possess additional functions compared with those of PTEN. Thus, the antiviral function of PTEN-L may open an avenue for the use of PTEN-L in antiviral therapy, particularly in patients with PTEN-deficient tumors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29057971      PMCID: PMC5827174          DOI: 10.1038/cmi.2017.102

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  29 in total

Review 1.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

2.  The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy.

Authors:  Prerna Malaney; Vladimir N Uversky; Vrushank Davé
Journal:  Mol Biosyst       Date:  2013-11

3.  The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I.

Authors:  Simon Rothenfusser; Nadege Goutagny; Gary DiPerna; Mei Gong; Brian G Monks; Annett Schoenemeyer; Masahiro Yamamoto; Shizuo Akira; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

4.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.

Authors:  H Sun; R Lesche; D M Li; J Liliental; H Zhang; J Gao; N Gavrilova; B Mueller; X Liu; H Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

6.  Inducible Rubicon facilitates viral replication by antagonizing interferon production.

Authors:  Yushun Wan; Wei Cao; Tao Han; Sheng Ren; Jian Feng; TieLong Chen; Jun Wang; Ruth Broering; Mengji Lu; Ying Zhu
Journal:  Cell Mol Immunol       Date:  2017-04-10       Impact factor: 11.530

Review 7.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

8.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  Systematic analysis of the PTEN 5' leader identifies a major AUU initiated proteoform.

Authors:  Ioanna Tzani; Ivaylo P Ivanov; Dmitri E Andreev; Ruslan I Dmitriev; Kellie A Dean; Pavel V Baranov; John F Atkins; Gary Loughran
Journal:  Open Biol       Date:  2016-05-25       Impact factor: 6.411

View more
  4 in total

Review 1.  Emerging role of PTEN loss in evasion of the immune response to tumours.

Authors:  Thiago Vidotto; Camila Morais Melo; Erick Castelli; Madhuri Koti; Rodolfo Borges Dos Reis; Jeremy A Squire
Journal:  Br J Cancer       Date:  2020-04-24       Impact factor: 7.640

2.  PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance.

Authors:  Luke Russell; Jessica Swanner; Alena Cristina Jaime-Ramirez; Yufeng Wang; Alex Sprague; Yeshavanth Banasavadi-Siddegowda; Ji Young Yoo; Gina M Sizemore; Raleigh Kladney; Jianying Zhang; Norman L Lehman; Michael C Ostrowski; Bangxing Hong; Michael Caligiuri; Jianhua Yu; Balveen Kaur
Journal:  Nat Commun       Date:  2018-11-27       Impact factor: 14.919

Review 3.  Multifaceted Regulation of PTEN Subcellular Distributions and Biological Functions.

Authors:  Tian Liu; Yiwei Wang; Yubing Wang; Andrew M Chan
Journal:  Cancers (Basel)       Date:  2019-08-26       Impact factor: 6.639

Review 4.  Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?

Authors:  Gunhild von Amsberg; Winfried Alsdorf; Panagiotis Karagiannis; Anja Coym; Moritz Kaune; Stefan Werner; Markus Graefen; Carsten Bokemeyer; Lina Merkens; Sergey A Dyshlovoy
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.